Linaptin5 mg

Linaptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is FDA-approved and guideline-supported for the following uses:

• Monotherapy: As initial therapy when metformin is not tolerated or is contraindicated (established use).
• Combination therapy: Added to metformin, a sulfonylurea, metformin plus a sulfonylurea, empagliflozin, or insulin when diet, exercise, and existing therapy do not provide adequate glycemic control (established, guideline-supported use, typically requiring combination with another antidiabetic agent for optimal effect).

Linaptin is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. It has not been studied for use in combination with insulin plus a sulfonylurea outside labeled combinations, and such off-label combinations should only be used under close physician supervision.

Each film-coated tablet contains Linagliptin 5 mg as the active ingredient, along with inactive excipients such as mannitol, pregelatinized starch, maize starch, copovidone, and magnesium stearate in the core, and hypromellose, titanium dioxide, talc, macrogol, and iron oxide (as coloring agent) in the film coat. Fixed-dose combination products containing Linagliptin with metformin or empagliflozin are also available; refer to the specific product label for exact composition.

Linaptin is an orally active, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor belonging to the 'gliptin' class of oral antidiabetic agents. It works by increasing the levels of active incretin hormones (GLP-1 and GIP), which help the body release more insulin and reduce glucagon secretion in a glucose-dependent manner, thereby lowering blood glucose levels in adults with type 2 diabetes mellitus.

A distinguishing pharmacokinetic feature of Linaptin, compared with other DPP-4 inhibitors such as sitagliptin, saxagliptin, and alogliptin, is that it is eliminated predominantly via the enterohepatic (biliary/fecal) route rather than the kidneys, with only a small fraction excreted unchanged in urine. As a result, no dose adjustment is generally required in patients with renal impairment, including those with severe renal impairment or end-stage renal disease.

Linaptin belongs to the therapeutic class of DPP-4 inhibitors (gliptins), a subgroup of oral antidiabetic agents that act as incretin enhancers. It is used for the management of type 2 diabetes mellitus.

Mechanism of Action

Linagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the rapid degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Linagliptin increases circulating concentrations of active GLP-1 and GIP, which in turn stimulate insulin release from pancreatic beta cells and suppress glucagon release from alpha cells, both in a glucose-dependent manner. This leads to improved postprandial and fasting glucose control with a low intrinsic risk of hypoglycemia when used alone.

Pharmacokinetics

• Absorption: Absolute bioavailability of approximately 30%; peak plasma concentration reached within 1.5 hours.
• Distribution: Extensive tissue distribution; binds strongly and saturably to DPP-4.
• Metabolism: Minimal hepatic metabolism (approximately 5%); the majority of the dose is excreted unchanged.
• Elimination: Predominantly eliminated unchanged via the enterohepatic (biliary/fecal) system, with only about 5% excreted unchanged in urine. Terminal half-life exceeds 100 hours (reflecting saturable DPP-4 binding), while the effective accumulation half-life supporting once-daily dosing is approximately 12 hours.

Linaptin tablets should be taken orally, once daily, with or without food, preferably at the same time each day to maintain consistent blood levels. Tablets should be swallowed whole with a glass of water; do not split, crush, or chew the tablet unless specifically advised by a physician. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped — do not double the dose.

The following clinically significant drug interactions have been established for Linaptin:

• Strong P-glycoprotein (P-gp) or CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's Wort): These significantly reduce plasma concentrations and efficacy of Linaptin by increasing its clearance. Use of an alternative antidiabetic treatment is recommended when co-administration with a strong inducer cannot be avoided.
• Insulin secretagogues (sulfonylureas) or insulin: Combining these with Linaptin increases the risk of hypoglycemia. A lower dose of the sulfonylurea or insulin may be required, with close blood glucose monitoring.

Common and important adverse effects reported with Linaptin include:

• Common: Nasopharyngitis, upper respiratory tract infection, cough, headache, diarrhea.
• Hypoglycemia: More common when Linaptin is combined with a sulfonylurea or insulin (see Interactions).
• Arthralgia (joint pain): Can occasionally be severe and disabling; onset may range from one day to years after starting therapy, and symptoms typically resolve after discontinuation (see Precautions and Warnings).
• Pancreatitis: Rare but serious, including fatal cases (see Precautions and Warnings).
• Bullous pemphigoid: Rare, serious skin reaction requiring drug discontinuation (see Precautions and Warnings).
• Hypersensitivity reactions: Rare cases of anaphylaxis, angioedema, and urticaria.

Pregnancy: There are limited data on the use of Linaptin in pregnant women. Animal reproduction studies have not shown adverse developmental effects at clinically relevant exposures, but this does not guarantee safety in humans. Linaptin should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician should always be consulted before use in pregnancy, and alternative therapies (such as insulin) are generally preferred for glycemic control during pregnancy.

Lactation: It is not known whether Linaptin is excreted in human breast milk, though it has been detected in the milk of lactating rats. Because many drugs pass into breast milk, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the benefit of breastfeeding and the mother's clinical need for Linaptin. Consult a physician before use while breastfeeding.

• Pancreatitis: Acute pancreatitis, including fatal cases, has been reported with Linaptin. Patients should be observed for signs and symptoms (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting); if suspected, discontinue Linaptin promptly and evaluate. Avoid use in patients with a history of pancreatitis unless no suitable alternative exists.
• Severe arthralgia: Severe and disabling joint pain has been reported; consider this diagnosis in patients who develop new joint pain while on Linaptin and discontinue if severe, as symptoms typically resolve after stopping the drug.
• Bullous pemphigoid: Cases requiring hospitalization have been reported. Advise patients to report development of blisters or erosions; if suspected, discontinue Linaptin and refer to a dermatologist.
• Heart failure: An increased risk of heart failure has been observed with other members of the DPP-4 inhibitor class. Consider the risks and benefits of Linaptin in patients with known risk factors for heart failure, and monitor for signs and symptoms.
• Hypoglycemia with combination therapy: Risk is increased when used with a sulfonylurea or insulin; dose reduction of these agents may be needed (see Interactions).
• Not for type 1 diabetes or diabetic ketoacidosis: Linaptin is not effective and should not be used in these settings.
• Macrovascular outcomes: No conclusive evidence of macrovascular risk reduction has been established with Linaptin.

There is limited clinical experience with overdose of Linaptin. In healthy volunteers, single doses far exceeding the therapeutic dose were generally well tolerated. If an overdose of Linaptin is suspected, seek immediate medical attention or contact emergency services / a poison control center. Management should consist of general supportive measures, including monitoring of vital signs and blood glucose, and removal of unabsorbed drug if appropriate. Because Linaptin is minimally dialyzable, hemodialysis or peritoneal dialysis is unlikely to be beneficial in overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: No dose adjustment of Linaptin is required at any stage of renal impairment, including severe renal impairment or end-stage renal disease, due to its predominantly non-renal elimination — a key distinguishing feature versus other DPP-4 inhibitors.
• Hepatic impairment: No dose adjustment is required for mild, moderate, or severe hepatic impairment.
• Elderly (65 years and older): No overall differences in safety or efficacy compared with younger patients; no dose adjustment required based on age alone, but renal function should be monitored.
• Pediatric patients (under 18 years): Safety and effectiveness have not been established; not recommended for use in this age group (see Pediatric Uses).

Linaptin is intended for long-term, chronic use in the management of type 2 diabetes mellitus, as part of an ongoing treatment plan alongside diet and exercise. Duration of therapy should be determined by the treating physician based on periodic assessment of glycemic control (e.g., HbA1c monitoring), tolerability, and overall treatment goals; it is not intended for short-term or as-needed use.

Linagliptin belongs to the following drug classes: Dipeptidyl peptidase-4 (DPP-4) inhibitors ('gliptins'); Incretin enhancers; Oral antidiabetic (hypoglycemic) agents.

Linagliptin selectively and reversibly inhibits the DPP-4 enzyme, preventing the rapid breakdown of the incretin hormones GLP-1 and GIP. This increases active incretin levels, which enhance glucose-dependent insulin secretion from pancreatic beta cells and reduce inappropriate glucagon secretion from alpha cells, resulting in improved glycemic control without a high inherent risk of hypoglycemia when used as monotherapy.

The safety and effectiveness of Linaptin have not been established in pediatric patients under 18 years of age. A randomized, controlled clinical trial of Linaptin in pediatric patients aged 10 to 17 years with type 2 diabetes did not demonstrate effectiveness in improving glycemic control. Therefore, Linaptin is not recommended for use in children or adolescents.